QDEL

8.3206.73%
KF

Kenneth F. Buechler

Independent Non-Executive Chairman

Dr. Kenneth F. Buechler, also known as Ken, Ph.D. Co-Founded Adnavance Technologies Inc. Dr. Buechler was previously the co-Founder of and held various roles at Biosite Inc. from 1988 until its acquisition by Alere Inc. in 2007, including serving as a Director and as President and Chief Scientific Officer, Senior Vice President, Research and Development, Vice President, Research and Director of Chemistry. He served as Senior Vice President of Research and Development at Biosite Incorporated from March 2003 to October 22, 2004; Vice President of Research and Development from April 2001 to March 2003; Vice President of Research from January 1994 to April 2001 and Director of Chemistry from April 1988 to January 1994. He has been Director at TriVirum, Inc. since 2020. He served as a Senior Research Scientist of the Diagnostics Research and Development Group at Hybritech Incorporated, where he was responsible for new product development and was the transfer project leader for ICON QSR CK-MB, a cardiac marker assay. In addition, Dr. Buechler was responsible for the design and synthesis of reagents for use in the first rapid, visual pregnancy test, the ICON hCG test. He served as Chairman of QuidelOrtho Corporation (formerly known as Quidel Corporation) since August 22, 2015 until May 2022. He served as the Chairman of Sequenom Inc. since April 1, 2015 until September 7, 2016. He serves as a Member of Advisory Board at MyoStim Inc. He has been a Director of Biosite Inc since June 2003. He served as Lead Independent Director at QuidelOrtho Corporation (formerly known as Quidel Corporation) since June 2022 until January 2023 and serves as its Non-Executive Chairman from December 11, 2022 and has been its Independent Director since November 2007. Dr. Buechler serves as a Director at Sotera Wireless, Inc. and Astute Medical Inc. He served as Director of Adnavance Technologies Inc. since April 2008 until April 2010. He served as Director of Sequenom Inc. since December 2009 until September 7, 2016. He serves as a Member of the American Chemical Society, the Biochemical Society, the International Federation of Clinical Chemistry and Laboratory Medicine and the American Association of Clinical Chemists. He is a Co-inventor of certain Biosite proprietary technologies, including the Triage Drugs of Abuse Panel and the Triage Meter Plus platform. Dr. Buechler holds a B.S. degree in Chemistry and a Ph.D. in Biochemistry from Indiana University.

Positions